학술논문
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas
Document Type
Article
Author
Source
In: Leukemia and Lymphoma . (Leukemia and Lymphoma, 2021, 62(5):1077-1087)
Subject
Language
English
ISSN
10292403
10428194
10428194